Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Argatroban
Drug ID BADD_D00161
Description Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban.
Indications and Usage Argatroban is indicated for prevention and treatment of thrombosis caused by heparin induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.
Marketing Status Prescription; Discontinued
ATC Code B01AE03
DrugBank ID DB00278
KEGG ID C04931
MeSH ID C031942
PubChem ID 92722
TTD Drug ID D07UWV
NDC Product Code 0078-0930; 68083-141; 0143-9288; 65145-126; 16729-430; 65219-429; 0409-1140; 55150-241; 70121-1037; 63323-526; 0143-9674; 25021-414; 0143-9377; 42023-182; 67457-212; 55486-1582; 76339-118; 45562-1124; 70333-1191; 0143-9559; 62227-015
Synonyms argatroban | MPQA | (2R,4R)-1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-2-piperidinecarboxylic acid monohydrate | MMTQAP | argatroban monohydrate | argatroban hydrate | Acova | (21R)-argatroban anhydrous | (2R,4R)-1-((2S)-5-((aminoiminomethyl)amino)-1-oxo-2-((((3R)-1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-2-piperidinecarboxylic acid | (21S)-argatroban anhydrous | (2R,4R)-1-((2S)-5-((aminoiminomethyl)amino)-1-oxo-2-((((3S)-1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-2-piperidinecarboxylic acid | (21S)-argatroban | (21R)-argatroban | MD 805 | MD805 | MD-805 | Novastan | argatroban anhydrous | (2R,4R)-1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-2-piperidinecarboxylic acid | MCI 9038 | MCI-9038
Chemical Information
Molecular Formula C23H36N6O5S
CAS Registry Number 74863-84-6
SMILES CC1CCN(C(C1)C(=O)O)C(=O)C(CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Headache17.14.01.001--
Hepatic failure09.01.03.0020.000097%
Hypersensitivity10.01.03.003--
Hypotension24.06.03.0020.000556%
Infection11.01.08.002--Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.005--Not Available
Ischaemic hepatitis24.04.07.004; 09.01.07.0180.000556%Not Available
Liver disorder09.01.08.0010.000371%Not Available
Liver function test abnormal13.03.01.0130.000371%Not Available
Melaena24.07.02.013; 07.12.02.0040.000371%Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial ischaemia02.02.02.008; 24.04.04.010--Not Available
Nausea07.01.07.001--
Pain08.01.08.004--
Peripheral ischaemia24.04.03.002--
Platelet count decreased13.01.04.0010.000742%
Pleural effusion22.05.02.002--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Prothrombin time prolonged13.01.02.0120.000371%Not Available
Prothrombin time shortened13.01.02.0130.000371%Not Available
Pulmonary embolism22.06.02.001; 24.01.06.0010.000927%Not Available
Pulmonary oedema22.01.03.003; 02.05.02.003--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000145%
Retroperitoneal haemorrhage07.07.02.002; 24.07.01.017--
Right ventricular failure02.05.03.0020.000097%Not Available
Sepsis11.01.11.003--
Septic shock24.06.02.011; 11.01.11.0040.000145%Not Available
Skin discolouration23.03.03.0050.000371%Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages